Abstract
Rheumatoid arthritis (RA) is an autoimmune disease involving antigen-specific T and B cells. Here, we perform single-cell RNA and repertoire sequencing on paired synovial tissue and blood samples from 12 seropositive RA patients. We identify clonally expanded CD4 + T cells, including CCL5+ cells and T peripheral helper (Tph) cells, which show a prominent transcriptomic signature of recent activation and effector function. CD8 + T cells show higher oligoclonality than CD4 + T cells, with the largest synovial clones enriched in GZMK+ cells. CD8 + T cells with possibly virus-reactive TCRs are distributed across transcriptomic clusters. In the B cell compartment, NR4A1+ activated B cells, and plasma cells are enriched in the synovium and demonstrate substantial clonal expansion. We identify synovial plasma cells that share BCRs with synovial ABC, memory, and activated B cells. Receptor-ligand analysis predicted IFNG and TNFRSF members as mediators of synovial Tph-B cell interactions. Together, these results reveal clonal relationships between functionally distinct lymphocyte populations that infiltrate the synovium of patients with RA.
Original language | English (US) |
---|---|
Article number | 4991 |
Journal | Nature communications |
Volume | 15 |
Issue number | 1 |
DOIs | |
State | Published - Dec 2024 |
Funding
A.H.J. receives research support from Amgen unrelated to the submitted work. K.Wei received a sponsored-research agreement from Gilead Sciences, 10X Genomics, and served as a consultant for Mestag Therapeutics and Santa Ana Bio. S.M.G. reports research support from Novartis and is a consultant for UCB unrelated to this work. G.S.F reports receiving grant support from Eli Lilly. V.M.H. is a co-founder of Q32 Bio and previously received research support from Janssen and was a consultant for Celgene and BMS, outside the submitted work. A.F. reports personal fees from Abbvie, Roche, and Janssen and grant support from Roche, UCB, Nascient, Mestag, GlaxoSmithKline and Janssen unrelated to this work. M.B.B. is a founder of Mestag Therapeutics and a consultant for GlaxoSmithKline, 4FO Ventures, and Scailyte AG. S.R is a founder of Mestag Therapeutics, a scientific adviser for Janssen and Pfizer, and a consultant for Gilead and Rheos Medicines, D.A.R. reports sponsored research from Janssen, Merck, and Bristol-Myers Squibb unrelated to the current work, and reports personal fees from Pfizer, Janssen, Merck, Scipher Medicine, GlaxoSmithKline, and Bristol-Myers Squibb and is co-inventor on a patent using T peripheral helper cells as a biomarker of autoimmune diseases. A.M.M. is a promotional speaker for Abbie and Pfizer, have developed educational content and speak for the National Psoriasis Foundation, and served as a consultant for CVS Caremark which none of this is relevant to this study. The remaining authors declare no competing interests.
ASJC Scopus subject areas
- General Chemistry
- General Biochemistry, Genetics and Molecular Biology
- General Physics and Astronomy